Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms.

IF 2.1 4区生物学 Q3 BIOCHEMICAL RESEARCH METHODS

PROTEOMICS – Clinical Applications Pub Date : 2023-11-01 Epub Date: 2023-08-31 DOI:10.1002/prca.202300048

Carlo Brogna, Simone Cristoni, Giuliano Marino, Luigi Montano, Valentina Viduto, Mark Fabrowski, Gennaro Lettieri, Marina Piscopo

{"title":"Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms.","authors":"Carlo Brogna, Simone Cristoni, Giuliano Marino, Luigi Montano, Valentina Viduto, Mark Fabrowski, Gennaro Lettieri, Marina Piscopo","doi":"10.1002/prca.202300048","DOIUrl":null,"url":null,"abstract":"Purpose: The SARS-CoV-2 pandemic prompted the development and use of next-generation vaccines. Among these, mRNA-based vaccines consist of injectable solutions of mRNA encoding for a recombinant Spike, which is distinguishable from the wild-type protein due to specific amino acid variations introduced to maintain the protein in a prefused state. This work presents a proteomic approach to reveal the presence of recombinant Spike protein in vaccinated subjects regardless of antibody titer.Experimental design: Mass spectrometry examination of biological samples was used to detect the presence of specific fragments of recombinant Spike protein in subjects who received mRNA-based vaccines.Results: The specific PP-Spike fragment was found in 50% of the biological samples analyzed, and its presence was independent of the SARS-CoV-2 IgG antibody titer. The minimum and maximum time at which PP-Spike was detected after vaccination was 69 and 187 days, respectively.Conclusions and clinical relevance: The presented method allows to evaluate the half-life of the Spike protein molecule \"PP\" and to consider the risks or benefits in continuing to administer additional booster doses of the SARS-CoV-2 mRNA vaccine. This approach is of valuable support to complement antibody level monitoring and represents the first proteomic detection of recombinant Spike in vaccinated subjects.","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e2300048"},"PeriodicalIF":2.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.202300048","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose: The SARS-CoV-2 pandemic prompted the development and use of next-generation vaccines. Among these, mRNA-based vaccines consist of injectable solutions of mRNA encoding for a recombinant Spike, which is distinguishable from the wild-type protein due to specific amino acid variations introduced to maintain the protein in a prefused state. This work presents a proteomic approach to reveal the presence of recombinant Spike protein in vaccinated subjects regardless of antibody titer.

Experimental design: Mass spectrometry examination of biological samples was used to detect the presence of specific fragments of recombinant Spike protein in subjects who received mRNA-based vaccines.

Results: The specific PP-Spike fragment was found in 50% of the biological samples analyzed, and its presence was independent of the SARS-CoV-2 IgG antibody titer. The minimum and maximum time at which PP-Spike was detected after vaccination was 69 and 187 days, respectively.

Conclusions and clinical relevance: The presented method allows to evaluate the half-life of the Spike protein molecule "PP" and to consider the risks or benefits in continuing to administer additional booster doses of the SARS-CoV-2 mRNA vaccine. This approach is of valuable support to complement antibody level monitoring and represents the first proteomic detection of recombinant Spike in vaccinated subjects.

查看原文本刊更多论文

SARS-CoV-2疫苗接种个体血液中重组刺突蛋白的检测:可能的分子机制

目的:SARS-CoV-2大流行促使新一代疫苗的开发和使用。其中，基于mRNA的疫苗由编码重组Spike的mRNA的可注射溶液组成，重组Spike与野生型蛋白不同，因为引入了特定的氨基酸变异来维持蛋白质处于预先状态。这项工作提出了一种蛋白质组学方法来揭示在接种疫苗的受试者中存在重组刺突蛋白，而不管抗体滴度如何。实验设计:使用生物样品的质谱检查来检测在接受mrna疫苗的受试者中是否存在重组刺突蛋白的特定片段。结果:在50%的生物样本中发现特异性的PP-Spike片段，其存在与SARS-CoV-2 IgG抗体滴度无关。接种后检测到PP-Spike的最短时间为69天，最长时间为187天。结论和临床意义:本文提出的方法可以评估刺突蛋白分子“PP”的半衰期，并考虑继续接种额外的SARS-CoV-2 mRNA疫苗的风险或益处。该方法为补充抗体水平监测提供了有价值的支持，并代表了首次在接种疫苗的受试者中检测重组Spike的蛋白质组学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PROTEOMICS – Clinical Applications 医学-生化研究方法

CiteScore

5.20

自引率

5.00%

发文量

审稿时长

1 months

期刊介绍： PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including: -basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease -the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers -the use of proteomics for the discovery of novel drug targets -the application of proteomics in the drug development pipeline -the use of proteomics as a component of clinical trials.